The European Commission just approved Incyte's Minjuvi combination for adults with relapsed or refractory follicular lymphoma. This makes it the first chemotherapy-free option of its kind for this patient group in Europe. The approval is based on results from the Phase 3 inMIND trial. Data showed that patients receiving the treatment had a median progression-free survival of 22.4 months, compared to 13.9 months for the control group. The safety profile was consistent with what they have seen in previous studies.